CAB-LA PrEP for breastfeeding women after delivery in Botswana
Official title: Linking HIV Prevention and post-partum care: Safety, efficacy and feasibility of cabotegravir-LA PrEP in high-risk breastfeeding population in Botswana
Funded at Beth Israel Deaconess Medical Center · NIH-11478445 · Data updated 2026-11-12
This study tests a long-acting HIV prevention shot for new mothers who are breastfeeding in Botswana to see if it prevents HIV safely and effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 24, 2021 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $368,830 |
| NIH project number | 3R01HD108047-05S1 |
| Project ID | NIH-11478445 on NIH RePORTER |
Who could benefit from this research
✓Could help
Women who are in the postpartum period, are breastfeeding, and are at high risk of HIV infection in Botswana.
✕Less likely to help
Women who are not at high risk of HIV or who cannot use PrEP for medical reasons may not benefit.
What this research studies
The research aims to reach young, breastfeeding women at high risk of HIV by starting Cabotegravir long-acting PrEP soon after birth and attaching follow-up PrEP care to postpartum and pediatric visits. It will examine safety during breastfeeding, how well the prevention method works in real-world postpartum care, and how feasible it is to implement this approach in clinics. The study includes close monitoring, adherence support, and integration with existing maternal-child health services to maximize uptake and continuity of PrEP during the breastfeeding period.
Why it matters
Potential benefit: If successful, the approach could reduce HIV infection risk for new mothers and decrease pediatric HIV transmission by protecting both mother and baby during breastfeeding.
How similar studies have gone: Early data show that long-acting CAB-LA PrEP can greatly reduce HIV risk compared with oral PrEP, supporting continued investigation in real-world settings.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Zash, Rebecca Marie — Beth Israel Deaconess Medical Center
- Study coordinator: Zash, Rebecca Marie
Related research
Other NIH-funded projects on the same topics.
-
CAB-LA PrEP for new mothers: safer HIV prevention for breastfeeding women in Botswana
A study tests a long-acting HIV prevention injection for breastfeeding women who are at high risk of HIV in Botswana.
-
Long-acting injectable HIV prevention for breastfeeding mothers
This project offers long-acting injectable cabotegravir to high-risk breastfeeding women starting at delivery, with follow-up through post-partum and baby-care clinics to prevent HIV.
-
Long-acting injectable HIV prevention for breastfeeding new mothers
This project looks at whether a long-acting injectable HIV prevention shot (cabotegravir) given after childbirth can safely protect breastfeeding women at high risk of HIV.
-
Exploring a new HIV prevention method for breastfeeding women in Botswana
This study is looking at a long-lasting injectable HIV prevention medication for breastfeeding women in Botswana to see if it’s safe and helps them stay protected from HIV while making it easier to get the care they need after having a baby.
-
Harnessing male peer networks to boost HIV testing and PrEP use
A large clinical trial in South Africa tests whether giving HIV self-test kits through male peer networks, with phone support, increases PrEP uptake among men.
-
Harnessing men's peer networks to boost HIV self-testing and PrEP use
A large project in South Africa tests whether giving HIV self-test kits through men’s social networks, with phone support, can lead to more men starting PrEP and using HIV testing.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.